Introduction {#s1}
============

The homeostasis of bone is maintained by the cooperative effects of two types of cells: osteoblasts for bone formation and osteoclasts for bone resorption ([@B5]). Imbalance of bone remodeling caused by an excessive number or overactive function of osteoclasts will eventually lead to many bone disorders, such as osteoporosis ([@B36]). Osteoporosis is a common skeletal disease featured by low bone density and increased fracture risk, and it affects about 200 million globally, leaving behind serious social and economic problems ([@B33]; [@B10]). However, the available treatments for osteoporosis are far from satisfactory ([@B41]). Therefore, the identification of novel agents or mechanisms targeting osteoclast differentiation and function has substantial clinical implications.

Osteoclasts are multinucleated cells originating from the monocyte/macrophage lineage regulated by the collaborative effects of macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL) ([@B3]). M-CSF maintains the survival and proliferation of osteoclasts ([@B37]), whereas RANKL provides signals essential for osteoclast precursor cells to differentiate into mature osteoclasts ([@B2]).

Previous studies have shed light on the multiple signaling pathways involved in RANKL-induced osteoclastogenesis. During osteoclast differentiation, MAPK and NF-κB signaling pathways are activated by the tumor necrosis factor receptor associated factor 6 (TRAF6), which is recruited *via* the interaction of RANKL and its receptor RANK on the surface of osteoclasts ([@B23]; [@B32]). Additionally, stimulation by RANKL also generates reactive oxygen species (ROS), which are crucial for osteoclast differentiation and bone resorption reportedly ([@B17]; [@B26]). Taken together, all these signaling cascades mentioned above participate in the regulation of osteoclastogenesis and contribute to the pathogenesis of osteoporosis and other osteoclast-related disorders.

Schisandrin B is a bioactive component isolated from the traditional Chinese medicine named Schisandra chinensis. Schisandrin B has shown varieties of biological and pharmacological properties, including antiinflammation and antioxidative activities ([@B14]; [@B43]). For instance, Schisandrin B has been reported to ameliorate chondrocytes inflammation and osteoarthritis by repression of MAPK and NF-κB pathways ([@B35]), indicating the potential mechanism of its antiinflammation property. In addition, a recent study revealed that Schisandrin B prevented diabetic nephropathy through suppressing oxidative stress ([@B31]). However, the precise role of Schisandrin B during RANKL-induced osteoclastogenesis remains obscure. In the current study, the role and the potential molecular mechanisms of Schisandrin B in osteoclast differentiation and function were investigated. Moreover, an estrogen deficiency-induced bone loss murine model was utilized to confirm the therapeutic effects of Schisandrin B on postmenopausal osteoporosis in mice.

Materials and Methods {#s2}
=====================

Reagents {#s2_1}
--------

Purified Schisandrin B (purity: 99.99%), extracted from Schisandra chinensis, was obtained from MedChemExpress (Monmouth Junction, NJ, USA). Recombinant murine M-CSF and RANKL were purchased from R&D Systems (Minneapolis, MN, USA). Antibodies against NFATc1, c-FOS, P38, JNK, ERK, P65, IκBα, p-P38, p-JNK, p-ERK, p-P65, and p-IκBα were obtained from Cell Signaling Technology (Beverly, MA, USA). Antibody targeting TRAP was purchased from Abcam (Cambridge, MA, USA). Antibodies against MMP9, Nrf2, HO1, NQO1, and β-Actin were from Proteintech Group (Wuhan, Hubei, China). Trap staining kit and other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Bone Marrow Macrophages (BMMs) Preparation and Osteoclastogenesis Assay {#s2_2}
-----------------------------------------------------------------------

Primary BMMs were obtained from bone marrow aspirates of 8-week-old C57BL/6 mice. In Brief, cells isolated from the femoral and tibial bone marrow were cultured in full α-MEM supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, and 30 ng/ml M-CSF. After 16 h, the supernatant cells were collected and maintained in the medium mentioned above for 2 days. The cells adhering to the bottom of the dishes were regarded as primary BMMs.

To generate osteoclasts, BMMs were further cultured in osteoclastogenic medium (α-MEM medium containing 30 ng/ml M-CSF and 75 ng/ml RANKL) for 5 days. Osteoclasts were then observed and analyzed using TRAP stanning kit according to the manufacturer's protocols.

Bone Marrow Stem Cells (BMSCs) Isolation and Osteoblast Differentiation Assay {#s2_3}
-----------------------------------------------------------------------------

Primary BMSCs were flushed out from bone marrow aspirates of 4-week-old C57BL/6 mice and cultured with basic α-MEM medium until confluent. Then the BMSCs were digested and seeded in 24-well plates at a density of 1×10^4^ cells/well. For osteoblast differentiation, the BMSCs were cultured in osteogenic medium (a-MEM medium containing 50 μM Ascorbic acid, 10 nM dexamethasone and 10 mM b-glycerol phosphate). ALP staining was performed on Day 7 and Alizarin Red staining was conducted on Day 21.

Cell Viability Assay {#s2_4}
--------------------

BMMs were seeded in 96-well plates at a density of 5×10^3^ cells/well and incubated overnight to adhere. The cells were then treated with different concentrations of Schisandrin B for the indicated times. The cytotoxicity of Schisandrin B was measured by replacing the culture medium with fresh medium containing 10% CCK 8 solution (Boster Biotechnology, Wuhan, Hubei, China) and incubating at 37°C for 1 h. The optical density at 450 nm was detected by a microplate reader (Bio-Tek, Winooski, VT, USA).

Pit Formation Assay {#s2_5}
-------------------

BMMs were seeded in an osteo assay surface coated with hydroxyapatite in a 96-well plate (Corning, NY, USA) at a density of 20,000 cells/well. Then the cells were cultured in osteoclastogenic medium for 5 days. After mature osteoclasts formed, various concentrations of Schisandrin B were incubated with osteoclasts. After 2 days, the plate was washed with 5% sodium hypochlorite and pit formation was quantitatively calculated through the resorption area.

F-Actin Ring Assay {#s2_6}
------------------

BMMs-derived osteoclasts cultured as previously described were fixed with immunol staining solution (Beyotime, Jiangsu, China) for 15 min and then permeabilized with 0.1% Triton X-100 for 5 min. Next, the cells were incubated with rhodamine‐conjugated phalloidin (Sigma-Aldrich) for 1 h at room temperature to visualize F‐actin. After staining with phalloidin, the nuclei were counterstained with DAPI for additional 5 min. F-actin rings were captured by a fluorescence microscope and total numbers per well were counted.

Adenoviral Transduction {#s2_7}
-----------------------

Adenoviruses carrying shRNA-targeting murine Nrf2 and control adenoviruses were purchased from Vigene Biosciences (Rockville, MD, USA). The shRNA sequence was as follows: 5′-CCGGCTTGAAGTCTTCAGCATGTTACTCGAGTAACATGCTGAAGACTTCAAGTTTTTT-3′.

For adenoviral transduction, BMMs were isolated as previously described and incubated in α-MEM medium with M-CSF supplementation. After 24 h, cells were washed and then cultured with adenoviral particles (100 particles per cell) for 12 h. Knockdown effects were confirmed by western blot.

Murine Ovariectomy (OVX)-Induced Bone Loss Model {#s2_8}
------------------------------------------------

12-week-old female C57BL/6 mice were obtained from the Animal Center of Tongji Hospital (Wuhan, China) and all animal studies were approved by the Ethics Committee of Tongji Hospital. 40 healthy mice were randomly distributed to four groups (n = 8): SHAM+VEH group (sham operation and vehicle treatment), SHAM+Sch B group (sham operation and Schisandrin B treatment), OVX+VEH group (OVX operation and vehicle treatment), and OVX+Sch B group (OVX operation and Schisandrin B treatment, 30 mg/kg). The dosage used in mice was based on a previous study and our preliminary experiments ([@B28]). One week after the surgery, mice were treated with Schisandrin B or vehicle by intragastrical gavage every other day. After 6 weeks, the mice were sacrificed to separate femurs and tibias for subsequent microcomputed tomography (micro-CT) scanning and histomorphometric analysis.

Micro-CT Scanning and Histologic Analysis {#s2_9}
-----------------------------------------

Femurs of each mouse were scanned using a Scanco vivaCT 40 micro-CT instrument (Scanco Medical, Bassersdorf, Switzerland). The scanning protocol was set at 100 kV, 98 μA, and 10 μm voxel size. Three-dimensional reconstruction results such as percentage bone volume/tissue volume (BV/TV), mean trabecular thickness (Tb.Th), mean trabecular space (Tb.Sp), and mean trabecular numbers (Tb.N) were measured using the reconstruction system provided with the micro-CT.

After micro-CT scanning, the femurs were fixed in 4% paraformaldehyde and decalcified with 10% EDTA. Finally, the paraffin-embedded bone was sectioned for TRAP staining.

RNA Isolation and Quantitative PCR {#s2_10}
----------------------------------

Total RNA was isolated from cultured cells by using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. One microgram of total RNA was synthesized using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, MA, USA). Real-time PCR was performed using SYBR Green Master Mix (Invitrogen). The primer sets used were as shown below (F, forward; R, reverse): NFATc1, F 5′-CAACGCCCTGACCACCGATAG-3′ and R 5′-GGGAAGTCAGAAGTGGGTGGA-3′; c-FOS, F 5′-CCAGTCAAGAGCATCAGCAA-3′ and R 5′-AAGTAGTGCAGCCCGGAGTA-3′; TRAP, F 5′-TACCTGTGTGGACATGACC-3′ and R 5′-CAGATCCATAGTGAAACCGC-3′; CTSK, F 5′-TGTATAACGCCACGGCAAA-3′ and R 5′-GGTTCACATTATCACGGTCACA-3′; MMP9, F 5′-TCCAGTACCAAGACAAAGCCTA-3′ and R 5′-TTGCACTGCACGGTTGAA-3′; CTR, F 5′-TGCTGGCTGAGTGCAGAAACC-3′ and R 5′-GGCCTTCACAGCCTTCAGGTAC-3′; DC-STAMP, F 5′-AAAACCCTTGGGCTGTTCTT-3′ and R 5′-AATCATGGACGACTCCTTGG-3′; V-ATPase, F 5′-GCCTCAGGGGAAGGCCAGATCG-3′ and R 5′-GGCCACCTCTTCACTCCGGAA-3′; GAPDH, F 5′-TCATTGACCTCAACTACATG-3′ and R 5′-TCGCTCCTGGAAGATGGTGAT-3′, Runx2, F 5'-GACTGTGGTTACCGTCATGGC-3' and R 5'-ACTTGGTTTTTCATAACAGCGGA-3'; Osx, F 5'-ATGGCGTCCTCTCTGCTTG-3' and R 5'-TGAAAGGTCAGCGTATGGCTT-3'; Alp, F 5'-CACGGCCATCCTATATGGTAA-3' and R 5'-GGGCCTGGTAGTTGTTGTGA-3'; Ocn, F 5'-CTGACCTCACAGATCCCAAGC-3' and R 5'-TGGTCTGATAGCTCGTCACAAG.

Western Blotting {#s2_11}
----------------

BMMs were treated with radio immunoprecipitation assay (RIPA) supplemented with 1 mM phenylmethanesulfonyl fluoride to extract proteins. Proteins were resolved on 10% SDS-PAGE gels, and the separated proteins were transferred onto PVDF membranes (Millipore, Billerica, MA, USA). After blocking with 5% BSA in TBS-0.1% Tween for 60 min, the membranes were incubated with indicated primary antibodies at 4°C overnight and secondary antibodies at 25°C for 60 min with gentle shaking. Antibody reactivity was detected by using electrochemical luminescence reagent (Thermo Scientific).

Measurement of ROS Level {#s2_12}
------------------------

The ROS level was determined by using a ROS assay kit (Beyotime) in accordance with the manufacturer's protocols. In brief, BMMs were incubated with various concentrations of Schisandrin B and stimulated with RANKL for 48 h. Subsequently, the cells were incubated with diluted DCFH-DA for 20min at 37°C in the dark and observed by a fluorescence microscope.

Statistical Analysis {#s2_13}
--------------------

Data are presented as means ± SD of three independent experiments. Statistical differences were analyzed by one-way ANOVA or Student's *t*-test, followed by Tukey's *post hoc* analyses. *P*\<0.05 was considered statistically significant.

Results {#s3}
=======

Schisandrin B Inhibits Osteoclast Differentiation {#s3_1}
-------------------------------------------------

The chemical structure of Schisandrin B was shown in [**Figure 1A**](#f1){ref-type="fig"}. To investigate the effects of Schisandrin B on osteoclastogenesis, the potential toxicity of Schisandrin B on BMMs was firstly measured. The CCK8 assay results revealed that the cell viability of BMMs treated with less than 20 μM Schisandrin B was not affected during RANKL-induced osteoclastogenesis ([**Figure 1B**](#f1){ref-type="fig"}). Next, we evaluated whether Schisandrin B could inhibit osteoclast differentiation. The trap staining results showed the formation of osteoclasts was remarkably inhibited by Schisandrin B in a dose-dependent manner at 520 μM ([**Figures 1C, D**](#f1){ref-type="fig"}). Osteoclast formation is a multistep process including proliferation, differentiation, fusion, and multinucleation. To test which stage was mainly suppressed by Schisandrin B, BMMs were treated with 20μM Schisandrin B at early (1--3 days), late (3--5 days), and whole stages (1--5 days) of osteoclast differentiation respectively. We found the inhibitory effects of Schisandrin B at the early stage of osteoclastogenesis were much stronger than those at the late stage ([**Figures 1E, F**](#f1){ref-type="fig"}).

![Schisandrin B inhibits osteoclast differentiation. **(A)** The chemical structure of Schisandrin B. **(B)** Bone marrow macrophages (BMMs) were treated with different concentrations of Schisandrin B (0, 5, 10, and 20 μM) for the indicated periods of time (1, 3, and 5 days). The cell viability was detected using CCK8 assay. **(C, D)** BMMs were treated with the indicated concentrations of Schisandrin B in the presence of macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL) for 5 days. TRAP-positive multinucleated osteoclasts were counted in the right column. **(E, F)** BMMs were treated with 20 μM Schisandrin B at early (1--3 days), late (3--5 days), and whole stages (1--5 days) of osteoclast differentiation in the presence of M-CSF and RANKL. TRAP-positive multinucleated osteoclasts were counted in the right column. The data were confirmed by three independent experiments and are expressed as means ± SD. \**P* \< 0.05, \*\**P* \< 0.01 versus the vehicle.](fphar-11-01175-g001){#f1}

Schisandrin B Suppresses Osteoclast Function {#s3_2}
--------------------------------------------

To further explore whether Schisandrin B impaired osteoclast function, F-actin ring assay and pit formation assay were conducted. F-actin is a characteristic structure formed when osteoclasts attach to the bone surfaces and it is a prerequisite for osteoclastic bone resorption ([@B25]; [@B44]). As shown in [**Figures 2A, C**](#f2){ref-type="fig"}, the numbers and the sizes of F‐actin rings were noticeably decreased by Schisandrin B treatment. Consistent with the results of F-actin ring assay, Schisandrin B also dramatically inhibited osteoclast-mediated resorption pits formation ([**Figures 2B, D**](#f2){ref-type="fig"}).

![Schisandrin B suppresses osteoclast function. **(A, B)** Bone marrow macrophages (BMMs) were cultured in the presence of macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL) until mature osteoclasts formed, followed by treatment with the indicated concentrations of Schisandrin B for additional 2 days. F-actin staining assay **(A)** or pit formation assay **(B)** was performed. **(C, D)** F-Actin ring numbers and resorption pit areas were quantified. The data were confirmed by three independent experiments and are expressed as means ± SD. \*\**P* \< 0.01 versus the vehicle.](fphar-11-01175-g002){#f2}

Schisandrin B Ameliorates OVX-Induced Bone Loss {#s3_3}
-----------------------------------------------

A murine model of estrogen deficiency-induced bone loss was utilized to mimic postmenopausal osteoporosis and micro-CT scanning was performed on the distal femurs of each mice to evaluate bone mass changes. Our results showed the OVX mice experienced a substantial loss of trabecular bone compared with the sham-operated mice. Meanwhile, Schisandrin B treatment in the OVX mice effectively attenuated the trabecular bone loss ([**Figure 3A**](#f3){ref-type="fig"}). Additionally, the OVX mice treated with Schisandrin B exhibited an increase in BV/TV, Tb.N, and Tb.Th, and a decrease in Tb.Sp in comparison to the mice receiving vehicle treatment ([**Figure 3B**](#f3){ref-type="fig"}). Next, TRAP staining was conducted to determine whether Schisandrin B protected against estrogen deficiency-induced bone loss by suppressing osteoclast differentiation. The TRAP-stained sections indicated that Schisandrin B reduced the numbers of TRAP-positive cells which were increased by estrogen deficiency ([**Figures 4A, B**](#f4){ref-type="fig"}).

![Schisandrin B attenuates ovariectomy-induced bone loss. **(A)** Representative micro-CT reconstruction results of the indicated four groups. **(B)** Micro-CT analyses of BV/TV, Tb.N, Tb.Th, and Tb.Sp in the region of interest. Data are presented as means ± SD. \*\**P* \< 0.01 versus the SHAM+VEH group. ^\#\#^*P* \< 0.01 versus the OVX+VEH group.](fphar-11-01175-g003){#f3}

![Schisandrin B reduces osteoclast formation in an ovariectomized murine model. **(A)** TRAP staining results of representative sections of distal femurs in the indicated four groups. **(B)** Bone histomorphometric analyses for number of osteoclasts per bone perimeter (N.Oc/B.Pm) and osteoclast surface per bone surface (Oc.S/BS). Data are presented as means ± SD. \*\**P* \< 0.01 versus the SHAM+VEH group. ^\#\#^*P* \< 0.01 versus the OVX+VEH group.](fphar-11-01175-g004){#f4}

Schisandrin B Downregulates Osteoclast-Related Genes Expression {#s3_4}
---------------------------------------------------------------

To further elucidate the effects of Schisandrin B on osteoclast differentiation, the expression of osteoclast specific genes including NFATc1, c-FOS, TRAP, MMP9, CTSK, CTR, DC-STAMP, and V-ATPase a3 was measured. Quantitative PCR results revealed the mRNA levels of these genes were all downregulated by Schisandrin B treatment ([**Figure 5A**](#f5){ref-type="fig"}). The inhibitory effects of Schisandrin B on osteoclast-related genes expression were further confirmed by western blot analysis, which showed that Schisandrin B dramatically suppressed the protein expression of these target genes during osteoclast differentiation ([**Figures 5B, C**](#f5){ref-type="fig"}).

![Schisandrin B downregulates osteoclast-related genes expression. **(A)** Bone marrow macrophages (BMMs) were treated with different concentrations of Schisandrin B (0, 5, 10, and 20 μM) in the presence of macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL) for 2 days. mRNA expression of osteoclast-related genes was measured by qPCR. **(B, C)** BMMs were cultured with or without 20μM Schisandrin B in the presence of M-CSF and RANKL for the indicated time periods. Protein expression of osteoclast-related genes was quantified using β-Actin as an internal control. The data were confirmed by three independent experiments and are expressed as means ± SD. \**P* \< 0.05, \*\**P* \< 0.01 versus the vehicle. ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 versus the Sch B (0 μM) + RANKL group.](fphar-11-01175-g005){#f5}

Schisandrin B Represses RANKL-Induced NF-κB, JNK, and ERK Phosphorylation {#s3_5}
-------------------------------------------------------------------------

To investigate the mechanisms involved in Schisandrin B-mediated suppression of osteoclastogenesis, the effects of Schisandrin B on NF-κB and MAPK pathways were detected. As shown in [**Figures 6A, B**](#f6){ref-type="fig"}, Schisandrin B markedly repressed NF-κB activation by inhibiting the degradation of IκBα and the phosphorylation of P65. As for the MAPK pathways, p-JNK and p-ERK were clearly decreased in Schisandrin B-treated BMMs, whereas the phosphorylation of P38 was not obviously affected by Schisandrin B treatment.

![Schisandrin B represses receptor activator of nuclear factor-κB ligand (RANKL)--induced NF-κB and mitogen activated protein kinase (MAPK) activation. **(A, B)** BMMs were starved in 0.5% FBS complete medium for 12 h. Then the cells were pretreated with or without Schisandrin B (20μM) for 24 h. Before the collection of protein extracts, BMMs were stimulated with RANKL for 0, 15, 30, or 60 min. The components of NF-κB and MAPK signaling pathways were measured by Western blotting. The data were confirmed by three independent experiments and are expressed as means ± SD. \**P* \< 0.05, \*\**P* \< 0.01 versus the vehicle.](fphar-11-01175-g006){#f6}

Schisandrin B Inhibits Oxidative Stress and Activates Nrf2 Signaling {#s3_6}
--------------------------------------------------------------------

Oxidative stress has been reported to play a vital role during osteoclast differentiation, so the influences of Schisandrin B on ROS production were evaluated. The generation of ROS induced by RANKL was strongly inhibited by Schisandrin B administration in a concentration-dependent manner ([**Figure 7A**](#f7){ref-type="fig"}). Nrf2 is known to modulate oxidative stress through induction of multiple antioxidant enzymes. Western blotting results showed the protein levels of Nrf2 and its target genes such as HO1 and NQO1 were enhanced by Schisandrin B independent of RANKL stimulation ([**Figures 7B, C**](#f7){ref-type="fig"}). To further confirm whether Schisandrin B inhibited osteoclastogenesis by activating Nrf2, a loss of function experiment was conducted. Firstly, knockdown effects of the adenovirus carrying Nrf2 shRNA were identified by western blot ([**Figure 7D**](#f7){ref-type="fig"}). Then the trap staining results revealed that the inhibitory effects of Schisandrin B on osteoclast differentiation were partially reversed by the adenovirus carrying Nrf2 shRNA ([**Figures 7E, F**](#f7){ref-type="fig"}).

![Schisandrin B inhibits oxidative stress and activates Nrf2 signaling. **(A)** Bone marrow macrophages (BMMs) were treated with the indicated concentrations of Schisandrin B in the presence of macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL) for 2 days. Cellular reactive oxygen species (ROS) levels were evaluated and quantified. **(B, C)** BMMs were treated with or without Schisandrin B (20μM) in the absence or presence of RANKL for 3 days. The protein was extracted for Western blotting. **(D)** Knockdown efficacy of adenoviral transduction. BMMs were infected with the adenovirus carrying Nrf2 shRNA or the control adenovirus for 3 days, and the expression of Nrf2 was measured using western blotting. **(E, F)** BMMs were treated with Schisandrin B (20μM), the adenovirus carrying Nrf2 shRNA, and the control adenovirus as indicated. After 5 days, TRAP staining was conducted. The data were confirmed by three independent experiments and are expressed as means ± SD. \**P* \< 0.05, \*\**P* \< 0.01 versus the vehicle. ^\#\#^*P* \< 0.01 versus the shRNA-con+ Schisandrin B (20μM) group.](fphar-11-01175-g007){#f7}

Discussion {#s4}
==========

Osteoporosis is a common bone disorder causing heavy burdens on global public health. Although great progress has been made in the treatment for osteoporosis, the toxic and side effects of current antiosteoporotic drugs cannot be ignored ([@B9]; [@B4]). Thus, it is necessary to develop effective and safe candidates to treat osteoporosis.

Schisandrin B, a major bioactive component of Schisandra chinensis, has strong antiinflammation and antioxidative properties ([@B14]; [@B43]). And it belongs to dibenzocyclooctadiene derivatives chemically. In general, Schisandrin B has shown various benefits in different organs and diseases, such as osteoarthritis, renal fibrosis, and myocardial ischemia ([@B35]; [@B45]; [@B8]), and it has been reported to regulate several signaling pathways, including NF-κB, MAPK, PI3K/AKT, and Nrf2/HO-1 pathways ([@B46]; [@B15]; [@B45]; [@B43]).

In the present study, the effects of Schisandrin B on osteoclast *in vitro* and *in vivo* were investigated. We found that Schisandrin B significantly inhibited osteoclast differentiation and function. Additionally, it exhibited no cytotoxicity during RNAKL-induced osteoclastogenesis. Moreover, treatment with Schisandrin B dramatically attenuated bone loss in an estrogen deficiency murine model and no deaths or side effects were observed during the intervention process. Previous studies have shown that other substances with antiosteoclastic activity, such as flavonoids, terpenoids, and alkaloids can also attenuate ovariectomy-induced bone loss ([@B6]; [@B19]; [@B42]). Collectively, these results indicated Schisandrin B might be a promising method for treating osteoporosis and other osteoclast-related diseases.

Osteoclastic bone resorption and osteoblastic bone formation maintain bone homeostasis together, so some experiments on osteoblast were performed as a supplement. In the current study, we found Schisandrin B can promote osteoclast differentiation ([**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}), and these results were partially in agreement with previous studies ([@B7]; [@B40]). Osteoblasts are derived from mesenchymal stem cells, and besides osteoblasts, mesenchymal stem cells can also differentiate into other cell types, including adipocytes, myocytes, and chondrocytes ([@B21]). A previous study showed that Gomisin N, extracted from Schisandra chinensis, reduced PPARγ expression and inhibited adipogenesis ([@B22]). Taken together, Schisandra chinensis showed osteoblastic and antiadipogenic activities reportedly.

MAPK and NF-κB are two crucial signaling cascades involved in RANKL-induced osteoclastogenesis ([@B16]; [@B12]; [@B29]). The binding of RANKL and its receptor RANK recruits TRAF6, eventually leading to the activation of MAPK and NF-κB pathways. The important role of Schisandrin B in the above pathways has been well established. For example, Schisandrin B was proved to ameliorate cardiac remodeling by suppressing MAPK signaling pathway ([@B1]). In addition, Schisandrin B was reported to improve the renal function of IgA nephropathy by repressing NF-κB pathway ([@B34]). Another study also showed Schisandrin B could attenuate vascular endothelial cells injury through regulation of NF-κB pathway ([@B30]). In the present study, the activation of MAPK and NF-κB signaling pathways was also inhibited by Schisandrin B, which is consistent with these previous studies. Our further investigation revealed that Schisandrin B suppressed the expression of NFATc1, c-FOS, TRAP, MMP9, CTSK, CTR, DC-STAMP, and V-ATPase, which are hallmarks of osteoclast differentiation.

ROS are reactive molecules formed from oxygen that contribute to various physiological and pathological conditions. They are produced by NADPH oxidase activation during RANKL-induced osteoclastogenesis and play essential roles of osteoclast formation ([@B38]; [@B11]). Nrf2 is a transcription factor involved in osteoclast differentiation by reducing ROS *via* induction of antioxidant enzymes such as HO1 and NQO1 ([@B20]; [@B39]). The critical effects of Schisandrin B on scavenging ROS has been proved. For example, Schisandrin B was reported to protect against liver injury by attenuating oxidative stress ([@B13]). Moreover, Schisandrin B can prevent endotheliocyte deficits by activating Nrf2 signaling ([@B18]). In the present study, ROS were scavenged by Schisandrin B in a dose-dependent manner. Meanwhile, Schisandrin B activated Nrf2 and promoted the expression of antioxidant enzymes, indicating that Schisandrin B suppressed osteoclastogenesis by eliminating ROS and activating Nrf2 signaling. Interestingly, we also found that the inhibitory effects of Schisandrin B on osteoclast differentiation were partially reversed by the adenovirus carrying Nrf2 shRNA, further elucidating the essential role of Nrf2 in Schisandrin B-mediated osteoclastogenesis repression.

Certain limitations of this study should be addressed despite the promising results. Schisandrin A, Schisandrin B, and Schisandrin C are the representative components of Schisandra chinensis. A previous study comparing Schisandrin A and Schisandrin B showed that only Schisandrin B resulted in the activation of Nrf2 ([@B27]), which is essential to osteoclastogenesis ([@B20]), so we selected Schisandrin B to investigate its role in osteoclast differentiation. And another study has also reported the inhibitory effect of Schisandra chinensis on osteoclastogenesis ([@B24]). Therefore, further studies investigating the differences and connections of the three components may help to better understand the exact function of Schisandra chinensis.

In conclusion, our study demonstrated Schisandrin B inhibited osteoclastogenesis *via* repression of MAPK and NF-κB pathways and scavenging of ROS *in vitro* and attenuated OVX-induced bone loss *in vivo*.
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The plant sample of Schisandrin B promotes osteoblast differentiation. BMSCs were cultured in osteogenic medium and treated with different concentrations of Schisandrin B as indicated. **(A)** representative Alizarin staining pictures, **(B)** representative ALP staining results, **(C)** mRNA levels of Runx2, Osx, Alp, and Ocn. \*Plt;0.05, \*\*P\<0.01 versus the vehicle.
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